APA (7th ed.) Citation

L, R., P, C., N, S., E, C., Z, V. d. W., A, B., . . . P, C. (2024). A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITL. Frontiers in immunology, 15, 1410638. https://doi.org/10.3389/fimmu.2024.1410638

Chicago Style (17th ed.) Citation

L, Ricard, et al. "A Combination of 5-azacytidine and Nivolumab Is a Potentially Effective Rescue Therapy in Relapsed/refractory AITL." Frontiers in Immunology 15 (2024): 1410638. https://doi.org/10.3389/fimmu.2024.1410638.

MLA (9th ed.) Citation

L, Ricard, et al. "A Combination of 5-azacytidine and Nivolumab Is a Potentially Effective Rescue Therapy in Relapsed/refractory AITL." Frontiers in Immunology, vol. 15, 2024, p. 1410638, https://doi.org/10.3389/fimmu.2024.1410638.